Berta Strulovici of Merck & Co. to Give Keynote Presentation at GTCbio’s 3rd Assay Development
Dr. Berta Strulovici, Vice President of Basic Research MRL, and Automated Biotechnology Head at Merck & Co. will give Keynote Presentation at GTCbio’s 4th Assay Development & Screening Technologies Conference, June 5-6, 2008 in San Francisco, CA.
San Francisco, CA, March 28, 2008 --(PR.com)-- Dr. Berta will present on the power of physiologically relevant biological assays translating from early drug discovery to the clinic. Her talk will show specific examples of the benefits of implementing complex, multiparametric cellular assays on a large, industrial scale, along the drug discovery pipeline from target ID to identifying potential responder populations. For target ID using RNAi technology, multiparametric assays generate biological activity profiles that provide valuable insight into complex disease models. Combined with miniaturization technologies and sophisticated data analysis tools, Dr. Berta and her group have identified novel targets for several therapeutic areas which are now either at target validation stage or have progressed to lead ID.
Attendees will receive a review of the benefits of integrating complex assay technologies from the early discovery phase to late in the pipeline and insight of Merck’s future strategy of profiling select compounds against disease-relevant cellular assays to identify novel activities for existing compounds.
GTCbio's 3rd Assay Development and Screening Technologies conference will provide attendees with critical information to utilize in the discovery and development of assays, while keeping them informed about the latest screening technologies for both high-throughput screening and high-content screening. Topics being covered include cell based assays, high throughput screening, high content screening, in vitro assays and screening, novel assay and screening technologies, and target validation. For more information visit www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, nina.tran@gtcbio.com
###
Attendees will receive a review of the benefits of integrating complex assay technologies from the early discovery phase to late in the pipeline and insight of Merck’s future strategy of profiling select compounds against disease-relevant cellular assays to identify novel activities for existing compounds.
GTCbio's 3rd Assay Development and Screening Technologies conference will provide attendees with critical information to utilize in the discovery and development of assays, while keeping them informed about the latest screening technologies for both high-throughput screening and high-content screening. Topics being covered include cell based assays, high throughput screening, high content screening, in vitro assays and screening, novel assay and screening technologies, and target validation. For more information visit www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, nina.tran@gtcbio.com
###
Contact
GTCbio
Nina Tran
626-256-6405
http://www.gtcbio.com
Nina Tran
626-256-6405
http://www.gtcbio.com
Contact
Categories